Vertex Pharmaceuticals Inc (VRTX.O) and partner Johnson & Johnson (JNJ.N) won European approval for their hepatitis C drug, Vertex said on Tuesday. The pill, which won U.S. approval in May, raked in strong sales of $75 million in the first five weeks it was sold in the country. Known as Incivek in the United States, it will be called Incivo in Europe. J&J has European rights to the product, with Vertex receiving royalties. Vertex holds exclusive rights to the drug in the United States.
